Summary
Updated Aug 31, 2026
Sheldon L. Koenig is President and CEO, Director of Esperion Therapeutics, Inc. (ESPR). 6 SEC Form 4 filings on record going back to 2024, most recently on 13 July 2026. Most recent open-market trade: sold $169K of ESPR on 18 June 2026. Lifetime open-market sales: $349K.
Recent Transactions
6Every recent SEC Form 4 transaction Sheldon L. Koenig has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Sheldon L. Koenig files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Benjamin Looker - $78K of ESPR open-market activity in the last 12 months
- Benjamin Halladay - $71K of ESPR open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Sheldon L. Koenig?
Sheldon L. Koenig is a corporate insider, tracked as President and CEO, Director of Esperion Therapeutics, Inc. (ESPR). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Sheldon L. Koenig submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Sheldon L. Koenig been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($349K) across all tracked filings.
Where can I see all of Sheldon L. Koenig's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Sheldon L. Koenig and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
